[go: up one dir, main page]

MX381994B - Inhibidor de janus quinasa. - Google Patents

Inhibidor de janus quinasa.

Info

Publication number
MX381994B
MX381994B MX2017013797A MX2017013797A MX381994B MX 381994 B MX381994 B MX 381994B MX 2017013797 A MX2017013797 A MX 2017013797A MX 2017013797 A MX2017013797 A MX 2017013797A MX 381994 B MX381994 B MX 381994B
Authority
MX
Mexico
Prior art keywords
janus kinase
kinase inhibitor
disclosed
jak
drugs
Prior art date
Application number
MX2017013797A
Other languages
English (en)
Other versions
MX2017013797A (es
Inventor
Lili Fan
Shuhui Chen
Hao Wu
Weiwei Mao
Yiqiang Huang
Original Assignee
Wuxi Fortune Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wuxi Fortune Pharmaceutical Co Ltd filed Critical Wuxi Fortune Pharmaceutical Co Ltd
Publication of MX2017013797A publication Critical patent/MX2017013797A/es
Publication of MX381994B publication Critical patent/MX381994B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se describen una serie de inhibidores de Janus quinasa, y particularmente se describe un compuesto o sales farmacéuticamente aceptables del mismo de Fórmula (I) y su uso en la preparación de fármacos para tratar enfermedades relacionadas con Janus quinasa (JAK). (ver Fórmula).
MX2017013797A 2015-05-29 2016-05-26 Inhibidor de janus quinasa. MX381994B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510289933 2015-05-29
CN201610344370 2016-05-23
PCT/CN2016/083426 WO2016192563A1 (zh) 2015-05-29 2016-05-26 Janus激酶抑制剂

Publications (2)

Publication Number Publication Date
MX2017013797A MX2017013797A (es) 2018-03-21
MX381994B true MX381994B (es) 2025-03-13

Family

ID=57440054

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013797A MX381994B (es) 2015-05-29 2016-05-26 Inhibidor de janus quinasa.

Country Status (17)

Country Link
US (1) US10174056B2 (es)
EP (1) EP3305788B1 (es)
JP (1) JP6564473B2 (es)
KR (1) KR102081272B1 (es)
CN (1) CN107531711B (es)
AU (1) AU2016271904B2 (es)
CA (1) CA2983481C (es)
DK (1) DK3305788T3 (es)
EA (1) EA036063B1 (es)
ES (1) ES2822748T3 (es)
HU (1) HUE050842T2 (es)
MX (1) MX381994B (es)
PL (1) PL3305788T3 (es)
PT (1) PT3305788T (es)
TW (1) TWI692481B (es)
UA (1) UA118822C2 (es)
WO (1) WO2016192563A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3033456C (en) * 2016-11-23 2021-03-09 Wuxi Fortune Pharmaceutical Co., Ltd Crystal forms and salt forms of 7h-pyrrolo[2,3-d]pyrimidine compounds and preparation method thereof
WO2019061299A1 (en) * 2017-09-29 2019-04-04 Rhodia Operations PROCESS FOR THE PREPARATION OF AMINOMETHYL-SUBSTITUTED HETEROCYCLOCCANE
CN107573364A (zh) * 2017-10-31 2018-01-12 无锡福祈制药有限公司 一种jak激酶抑制剂
CN107602590A (zh) * 2017-10-31 2018-01-19 无锡福祈制药有限公司 具有Janus激酶抑制活性的桥环化合物
CN107652308A (zh) * 2017-10-31 2018-02-02 无锡福祈制药有限公司 一种Janus激酶3抑制剂
CN107778321A (zh) * 2017-10-31 2018-03-09 无锡福祈制药有限公司 一种托法替尼类似物
CN107602591A (zh) * 2017-10-31 2018-01-19 无锡福祈制药有限公司 一种Janus激酶3抑制剂
CN107805259A (zh) * 2017-10-31 2018-03-16 无锡福祈制药有限公司 一种吡咯并嘧啶类化合物
PT3915989T (pt) * 2019-01-30 2023-10-02 Felicamed Biotechnology Co Ltd Inibidor de jak e método de preparação do mesmo
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
EP3981769A4 (en) 2019-06-05 2023-07-19 Guangzhou Joyo Pharmatech Co., Ltd PYRROLOPYRIMIDINE COMPOUND AND USE
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
CN111004236B (zh) * 2019-12-19 2022-04-05 卓和药业集团股份有限公司 一种wxfl10203614中间体的动态动力学拆分方法
CN110923288A (zh) * 2019-12-19 2020-03-27 卓和药业集团有限公司 一种wxfl10203614中间体的生物学拆分方法
CN111039963B (zh) * 2019-12-31 2021-03-19 卓和药业集团有限公司 Wxfl10203614水溶性类似物及其合成方法
CN111087412B (zh) * 2019-12-31 2021-04-09 卓和药业集团有限公司 一类吡咯并嘧啶衍生物及其合成方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN112168827A (zh) * 2020-11-03 2021-01-05 卓和药业集团有限公司 一种用于治疗银屑病的药物组合物及其制备方法
CN113372343B (zh) * 2020-12-04 2022-07-29 广州嘉越医药科技有限公司 一种吡咯并嘧啶类化合物中间体及其制备方法
CN114591333B (zh) * 2020-12-04 2023-08-01 广州嘉越医药科技有限公司 一种吡咯并嘧啶类化合物的制备方法
CN113372366B (zh) * 2020-12-04 2022-08-30 广州嘉越医药科技有限公司 一种吡咯并嘧啶类化合物的盐、其晶型及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA005852B1 (ru) * 1998-06-19 2005-06-30 Пфайзер Продактс Инк. ПИРРОЛО[2,3-d]ПИРИМИДИНЫ
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
SK287188B6 (sk) * 1999-12-10 2010-02-08 Pfizer Products Inc. Pyrolo [2,3-d]pyrimidínová zlúčenina, jej použitie a farmaceutická kompozícia alebo kombinácia s jej obsahom
JP4579497B2 (ja) 2000-12-01 2010-11-10 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド アデノシンａ１、ａ２ａ、およびａ３受容体に特異的な化合物、ならびにそれらの使用
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
KR101335843B1 (ko) 2008-08-20 2013-12-02 조에티스 엘엘씨 피롤로[2,3-ｄ]피리미딘 화합물
JP5709276B2 (ja) * 2009-04-20 2015-04-30 オースペックス ファーマシューティカルズ，エルエルシー ヤヌスキナーゼ３のピペリジンインヒビター
TW201111385A (en) * 2009-08-27 2011-04-01 Biocryst Pharm Inc Heterocyclic compounds as janus kinase inhibitors
CN102985424B (zh) 2010-04-14 2015-03-11 阵列生物制药公司 5,7-取代的-咪唑并[1,2-c]嘧啶
AU2012323399A1 (en) 2011-10-12 2014-05-29 Array Biopharma Inc. 5,7-substituted-imidazo[1,2-c]pyrimidines
CN104114553B (zh) * 2011-12-12 2017-03-01 雷迪博士实验室有限公司 作为原肌球蛋白受体激酶(Trk)抑制剂的取代的吡唑并[1,5‑a]吡啶
SI2796460T1 (sl) * 2011-12-21 2018-10-30 Jiangsu Hengrui Medicine Co. Ltd Pirolni šestčlenski derivat heteroarilnega obroča, postopek priprave zanj in medicinske uporabe le-tega
US8551542B1 (en) 2012-09-20 2013-10-08 Basic Research L.L.C. Methods and compositions for increasing growth hormones
SI3290421T1 (sl) * 2013-02-22 2019-03-29 Pfizer Inc. Kombinacija derivatov pirolo (2,3-D)pirimidina z enim ali več dodatnimi sredstvi za zaviranje z janusom povezane kinaze (JAK)
NZ708593A (en) * 2013-02-27 2018-01-26 Mochida Pharm Co Ltd Novel pyrazole derivative
MA39092B1 (fr) * 2013-12-05 2018-09-28 Pfizer Pyrrolo[2,3-d]pyrimidinyle, pyrrolo[2,3-b]pyrazinyle et pyrollo[2,3-d]pyridinyle acrylamides
PT3539965T (pt) 2013-12-09 2021-04-07 Unichem Lab Ltd Processo melhorado para a preparação de (3r,4r)-(1-benzil-4-metilpiperidin-3-il)-metilamina
WO2015188369A1 (en) * 2014-06-13 2015-12-17 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta

Also Published As

Publication number Publication date
US20180162879A1 (en) 2018-06-14
EP3305788A1 (en) 2018-04-11
AU2016271904A1 (en) 2017-11-09
DK3305788T3 (da) 2020-09-28
ES2822748T3 (es) 2021-05-04
JP2018516264A (ja) 2018-06-21
EA201792116A1 (ru) 2018-07-31
EA036063B1 (ru) 2020-09-22
PL3305788T3 (pl) 2021-03-08
KR20170141787A (ko) 2017-12-26
TWI692481B (zh) 2020-05-01
PT3305788T (pt) 2020-09-25
KR102081272B1 (ko) 2020-02-25
MX2017013797A (es) 2018-03-21
CN107531711A (zh) 2018-01-02
US10174056B2 (en) 2019-01-08
UA118822C2 (uk) 2019-03-11
EP3305788A4 (en) 2018-11-07
JP6564473B2 (ja) 2019-08-21
WO2016192563A1 (zh) 2016-12-08
EP3305788B1 (en) 2020-08-05
TW201706277A (zh) 2017-02-16
CN107531711B (zh) 2020-03-31
CA2983481C (en) 2020-04-14
HUE050842T2 (hu) 2021-01-28
CA2983481A1 (en) 2016-12-08
AU2016271904B2 (en) 2018-05-10

Similar Documents

Publication Publication Date Title
MX381994B (es) Inhibidor de janus quinasa.
UA118149C2 (uk) Інгібітор jak
EA201890318A1 (ru) СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
SA518400547B1 (ar) مشتقات بيرازولو بيريميدين كمثبط كيناز
MX382927B (es) Compuestos de benzolactama como inhibidores de la proteína cinasa.
WO2017075629A3 (en) Wee 1 kinase inhibitors and methods of making and using the same
MX389672B (es) Inhibidores de ssao de aminopirimidina
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
MX2016008688A (es) Compuestos terapéuticos inhibidores.
MX2018000396A (es) Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4).
MX381342B (es) Compuestos terapeuticos inhibidores.
EA201990833A1 (ru) Соединение пиридина
PH12019501022A1 (en) Pyrazolopyrimidine compounds and methods of use thereof
MX374439B (es) Compuesto de piridona como inhibidor de c-met
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
WO2016004413A3 (en) Gls1 inhibitors for treating disease
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
EA201990313A1 (ru) Производное триазолопиразинона, пригодное в качестве ингибитора фдэ1 человека
MY193239A (en) Novel b-lactamase inhibitors
MX394038B (es) Derivados de pirrolotriazina como inhibidores de cinasas.
MY180727A (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzeimer?s disease
MX389403B (es) Inhibidor del receptor del factor de crecimiento de fibroblastos 4 (fgfr4) y metodo de preparacion y uso del mismo
MX2019014773A (es) Inhibidores de ccl2.
NZ780408A (en) Human plasma kallikrein inhibitors
MY192305A (en) Bipyrazole derivatives as jak inhibitors